No Man

Sign in

Join Free
Post RFQ

Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

TypeName: Business Offer

Category:

Country: United States

Summary: This ADC product is comprised of a Inotuzumab conjugated via a hydrazone linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage. http://www.creative-biolabs.com/adc/target-cd22-10.htm

Description: [RequestDescription]

OfferId: 2556

Name:Creative Biolabs

Telphone:

Email:[email protected]